100,000 Lexaria (LEXX) shares gifted back to the company
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Lexaria Bioscience Corp. director Christopher Bunka reported a bona fide gift of 100,000 common shares back to Lexaria, which were returned to the company’s treasury. This was not an open‑market sale and carried no stated share price.
After the gift, Bunka holds 273,543 common shares directly and 281,912 common shares indirectly through a private holding company as of the reported date. He also retains multiple stock option awards over additional common shares, with exercise prices between 1.0400 and 3.0000 per share and expirations from 2026 through 2030.
Positive
- None.
Negative
- None.
Insider Trade Summary
100,000 shares gifted
Mixed
10 txns
Insider
BUNKA CHRISTOPHER
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Gift | common shares | 100,000 | $0.00 | -- |
| holding | Stock Options | -- | -- | -- |
| holding | Stock Options | -- | -- | -- |
| holding | Stock Options | -- | -- | -- |
| holding | Stock Options | -- | -- | -- |
| holding | Stock Options | -- | -- | -- |
| holding | Stock Options | -- | -- | -- |
| holding | Stock Options | -- | -- | -- |
| holding | common shares | -- | -- | -- |
| holding | common shares | -- | -- | -- |
Holdings After Transaction:
common shares — 273,543 shares (Direct);
Stock Options — 26,000 shares (Direct);
common shares — 281,912 shares (Indirect, Private Holding Company)
Footnotes (1)
- [object Object]
FAQ
What insider transaction did Christopher Bunka report for Lexaria Bioscience (LEXX)?
Christopher Bunka reported a bona fide gift of 100,000 Lexaria common shares back to the company, which were returned to treasury. This Form 4 shows a non-market transfer, not an open-market trade, and updates his direct and indirect share ownership.
What Lexaria (LEXX) stock options does Christopher Bunka still hold according to this filing?
The filing lists several stock option awards over Lexaria common shares, with exercise prices between $1.0400 and $3.0000 per share. These options have stated expiration dates ranging from 2026 through 2030 and represent additional potential equity exposure beyond his current shareholdings.